company:novo-nordisk Novo Nordisk patent protections lapse in Canada Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
category:side-effects Ozempic is not likely to directly enlarge the male appendage. A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
research STRIDE study: GLP1s vs peripheral artery disease (PAD) Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
category:watercooler Shortages threaten corporate profits, likely to end soon We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news Ozempic approved for Chronic Kidney Disease The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
government Government Price negotiations on Ozempic and Wegovy The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
drug:ozempic Semaglutide (Ozempic) vs Tirzepatide (Mounjaro) Learn the major differences between Ozempic (Semaglutide) and Mounjaro (Tirzepatide)
